New Darza­lex for­mu­la­tion wins FDA ap­proval; Is­raeli biotech plans $50M IPO

→ Dur­ing the Covid-19 cri­sis, drugs that must be ad­min­is­tered in hos­pi­tal set­tings or take hours to be in­fused are see­ing de­layed up­take as health care fa­cil­i­ties are filled to the brim with coro­n­avirus pa­tients. Can­cer drugs, such as J&J and part­ner Gen­mab’s block­buster Darza­lex, come in an IV ver­sion that takes sev­er­al hours to ad­min­is­ter. How­ev­er, on Fri­day, the FDA ap­proved a sub­cu­ta­neous ver­sion of the mul­ti­ple myelo­ma ther­a­py — pow­ered by Halozyme Ther­a­peu­tics‘ drug de­liv­ery tech­nol­o­gy — that brings that time down to three to five min­utes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER